• Natera reported new JAMA Oncology data showing its Signatera MRD test predicted an overall survival benefit from adjuvant chemotherapy in resected colorectal liver metastases.
• In 298 GALAXY trial patients with 43-month median follow-up, MRD-positive patients saw improved OS with chemotherapy vs observation (adjusted HR 0.27; P=0.03).
• 48-month OS was 65.3% with chemotherapy vs 32.9% with observation in MRD-positive patients who had upfront surgery without neoadjuvant chemotherapy.
• MRD-negative patients had favorable outcomes with no observed survival benefit from adjuvant chemotherapy.
• Post-surgical MRD positivity 2-10 weeks after surgery was strongly prognostic for worse OS, with hazard ratios above 9 across key subgroups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260706515913) on July 06, 2026, and is solely responsible for the information contained therein.